Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States

Transplantation

Volumn 90, Issue 12, 2010, Pages 1420-1426

  Blumberg, Emily A ^a   Hauser, Ingeborg A ^b   Stanisic, Sanja ^c   Mueller, Elvira ^c   Berenson, Karina ^d   Gahlemann, Christoph G ^e   Humar, Atul ^f   Jardine, Alan G ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c Analytica International Inc   (Germany)

^d Analytica International   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CMV; Economics; Infection; Kidney renal; Transplantation

Indexed keywords

VALGANCICLOVIR;

ARTICLE; CLINICAL EVALUATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; HUMAN; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MODELS, ECONOMIC; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 78650835480     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ff500d     Document Type: Article

References (46)

1. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9: S78.
2. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
3. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
4. Dmitrienko S, Balshaw R, Machnicki G, et al. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines. Transplantation 2009; 87: 570.
5. Griffiths PD. Cytomegalovirus therapy: Current constraints and future opportunities. Curr Opin Infect Dis 2001; 14: 765.
6. Griffiths PD, Whitley RJ. Management of cytomegalovirus infections in transplant patients. Herpes 2000; 7: 42.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
8. Hodson EM, Craig JC, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008: CD003774.
9. Dmitrienko S, Yu A, Balshaw R, et al. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int 2007; 72: 1014.
10. Oppenheimer F, Gonzalez-Molina M, Rubio M. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. Clin Transplant 2007; 21: 441.
11. Akalin E, Bromberg JS, Sehgal V, et al. Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004; 4: 148.
12. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
13. Helanterä I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 316.
14. Luan FL, Stuckey LJ, Park JM, et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449.
15. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
16. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a qualityadjusted life year: In search of a standard. Med Decis Making 2000; 20: 332.
17. Laufer F. Thresholds in cost-effectiveness analysis-More of the story. Value Health 2005; 8: 86.
18. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761.
19. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 2005; 9: 1, iii-iv.
20. Legendre C, Beard SM, Crochard A, et al. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ 2005; 6: 172.
21. Tilden DP, Chapman J, Davey PJ, et al. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant 2004; 18: 312.
22. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
23. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
24. Morton RL, Howard K, Webster AC, et al. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant 2009; 24: 2258.
25. Earnshaw SR, Graham CN, Irish WD, et al. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol 2008; 19: 1807.
26. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programs [ed. 3]. Oxford, Oxford University Press 2005.
27. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
28. Howard K, Salkeld G, White S, et al. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology (Carlton) 2009; 14: 123.
29. Opelz G, Döhler B; Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85: 661.
30. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
31. Pallardó Mateu LM, Sancho CA, Capdevila PL, et al. Acute rejection and late renal transplant failure: Risk factors and prognosis. Nephrol Dial Transplant 2004; 19(suppl 3): iii38.
32. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21: 309.
33. Ansell D, Roderick P, Hodsman A, et al.UKRenal Registry 11th Annual Report (December 2008): Chapter 7 survival and causes of death of UK adult patients on renal replacement therapy in 2007: National and centre- specific analyses. Nephron Clin Pract 2009; 111: c113.
34. Kidney Kaplan-Meier Patient Survival Rates For Transplants Performed: 1997-2004, based on OPTN data as of October 17, 2009. OPTN: Organ ProcurementandTransplantationNetwork.2009.Availableat:http://optn. transplant.hrsa.gov/latestData/step2.asp. Accessed October 21, 2009.
35. Nett PC, Heisey DM, Fernandez LA, et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036.
36. U.S. Bureau of Labor Statistics. Inflation Calculator. United States Department of Labor 2010. Available at: http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed December 1, 2009.
37. Boyd S, Martin JE, First MR, et al. Health utility scores following renal transplantation; a comparison of methods. Transplantation 2000; 69: 23.
38. Boyd SR, Martin JE, First MR, et al. Health utility scores following renal transplantation. Transplant Proc 2001; 33: 1900.
39. Girardi V, Schaedeli F, Marti HP, et al. The willingness of patients to accept an additional mortality risk in order to improve renal graft survival. Kidney Int 2004; 66: 375.
40. Greiner W, Obermann K, Schulenburg JM. Socio-economic evaluation of kidney transplantation in Germany. Arch Hell Med 2001; 18: 147.
41. Jofre R, Lopez-Gomez JM, Moreno F, et al. Changes in quality of life (QoL) after kidney transplantation (KT) in the long term. Nephrol Dial Transplant 2000; 15: A270.
42. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003; 76: 1699.
43. Knoll GA, Nichol G. Dialysis, kidney transplantation, or pancreas transplantation for patients with diabetes mellitus and renal failure: A decision analysis of treatment options. J Am Soc Nephrol 2003; 14: 500.
44. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008; 86: 85.
45. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: A systematic review and metaanalysis. Value Health 2008; 11: 733.
46. Neipp M, Karavul B, Jackobs S, et al. Quality of life in adult transplant recipients more than 15 years after kidney transplantation. Transplantation 2006; 81: 1640.